You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on lung cancer.
In PLOS this week: variations in the way synonymous DNA codons are used in yeast, links between germline TP53 mutations and recurrent somatic mutations in bladder cancer, and more.
The firm has joined forces with AstraZeneca, the IASLC, and the Global Lung Cancer Coalition, with a goal to double five-year survival rates by 2025.
Re-expression of DUX4, which is normally silenced in somatic tissues, appeared to stymie MHC class I-related immune activity in several solid cancer types.
The study plans to recruit close to 300 patients with advanced non-small cell lung cancer, with half being treated based on liquid biopsy results.
A proof-of-principle study suggests metabolite clusters may differ in non-small cell lung cancer patients depending on tumor type, disease stage, and overall survival trajectory.
The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
The World Health Organization has updated its list of essential medicines, Reuters reports.
Under the agreement, Biodesix will use the Thermo Fisher Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to generate data to apply for FDA premarket approval.
The firm said it needs more time to ensure that the DetermaVu assay is providing the most consistent and sensitive results for patients.
At the WIN Symposium, a researcher from Sheba Medical Center discussed ongoing efforts to develop a 22-gene signature for predicting brain metastasis in NSCLC.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.